FDA warning letters in Ireland: which Irish sites received one and what happens next

What an FDA warning letter is, compared with a Form 483 and an import alert

A warning letter is the FDA's main tool for getting a company to fix serious problems before it takes enforcement action. A Form 483 comes earlier, at the end of an inspection, and an import alert is a border measure that stops products entering the US.

The FDA's Regulatory Procedures Manual says warning letters are issued "only for violations of regulatory significance", meaning violations "that may lead to enforcement action if not promptly and adequately corrected". A letter is "informal and advisory" and does not commit the FDA to enforcement.

Source: FDA Regulatory Procedures Manual, chapter 4 (July 2024); FDA Form 483 FAQ; FDA import alerts page; FDA, About Warning and Close-Out Letters.

Import alerts reach Irish firms too. The FDA's import alert 66-40, for drugs from firms that have not met GMP, lists one Irish firm: Europharma Concepts Limited of Clara, Co. Offaly, added on 22 February 2018 and still listed when we checked in October 2026.

FDA warning letters to sites in Ireland, 2021 to 2026

Two warning letters went to manufacturing sites on the island of Ireland in the period we could check. We read the recipient address on every non-tobacco letter in the FDA's warning letter list on 6 October 2026: 2,515 letters dated 4 January 2021 to 25 September 2026.

Source: FDA warning letters to Randox Laboratories Limited (6 December 2024) and Genzyme Ireland Limited (22 June 2026), fda.gov, read 6 October 2026.

What this list does not cover

The list is short, and it has limits. The FDA's searchable list starts in January 2021, so we could not check 2019 and 2020 in the same way, and targeted searches found no letter to an Irish manufacturing site in those years. The most recent earlier letter we found to an Irish drug plant went to Europharma Concepts in Co. Offaly on 16 May 2018, after an inspection from 31 October to 3 November 2017. Letters about food and tobacco are left out because they do not concern medicine or device plants.

Two letters is a small number for an island with 331 operating manufacturing sites on our Ireland pharma map.

Patterns in the Irish letters

Both letters are about weak investigation and follow-up, not a single bad batch. In each case the FDA said the firm's replies to the Form 483 fixed individual points but missed the system behind them.

• Investigations and CAPA. Genzyme "cancelled numerous deviations without investigating the root cause or assessing product impact". At Randox, the FDA said the firm had not identified corrective and preventive actions for a carryover CAPA, nor how it would check that they worked.
• The system, not the symptom. The FDA told Genzyme its response "lacks a comprehensive plan that addresses the root cause" of the quality unit's failure. It told Randox its corrective action "must address systemic problems".
• Records you can trust. Genzyme's letter centres on data integrity: environmental monitoring logs that did not match cleanroom entry times, and review checklists that were discarded.

These are the same weak points our guide to CAPA and root cause analysis covers. For the rules cited, see our summaries of 21 CFR 211 and 21 CFR 820. Since 2 February 2026, device plants work to the FDA's Quality Management System Regulation, which replaced the 820.100 CAPA section cited in the Randox letter.

What happens after an FDA warning letter

The firm replies, the FDA judges the reply, and the letter stays open until the FDA has verified the fixes, usually by inspecting again. Only then does it issue a close-out letter.

The FDA's page About Warning and Close-Out Letters says a close-out letter "will not be issued based on representations that some action will or has been taken" and that "usually, the standard for verifying that corrections have been implemented will be a follow-up inspection". If later inspections find violations, enforcement can follow without further notice.

The Genzyme Waterford case

The timeline shows how long the process runs. The FDA inspected the Waterford site from 12 to 20 January 2026 and issued a Form 483. Genzyme replied on 10 February, 26 February and 8 April 2026, and the warning letter followed on 22 June 2026.

The letter asked Genzyme to reply within 15 working days, to assess data integrity across all operations and to widen its review of cancelled deviations. It warned that failure to fix the problems "may result in action without further notice including, without limitation, seizure and/or injunction". When we checked FDA's list on 6 October 2026, no response or close-out letter was posted for either Irish letter. Read our analysis of the Sanofi Waterford warning letter, the Sanofi Ireland company page and the sites on our Waterford map.

How HPRA inspections relate to FDA inspections

For medicines, the FDA can rely on HPRA inspections instead of sending its own investigators, under the EU-US mutual recognition agreement. The FDA confirmed Ireland's capability on 1 June 2018, according to the EMA.

The agreement does not stop FDA visits. The FDA's MRA questions and answers say both sides "reserve the right to inspect at any time and in any country", though surveillance inspections should be "the exception rather than the rule". The Genzyme inspection is an example. Its scope covers human drugs, biologics and veterinary drugs, so device makers such as Randox remain in the FDA's own inspection programme.

The HPRA's own process runs on a similar pattern to a Form 483. Sites usually get 4 to 6 weeks' notice, inspections typically last 3 to 5 days, and a report follows within three weeks. Deficiencies are graded critical, major or other, and the site must reply within about three weeks with a root cause analysis and a CAPA plan. For US recalls, see our FDA recalls register.